Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años

La fibrilación auricular no valvular (FANV) es la arrimia cardiaca más frecuente y su prevalencia aumenta proporcionalmente con la edad. Esta se relaciona con desenlances desfavorables como muerte, accidentes cerebrovasculares (ACV) y discapacidad. Aproximadamente el 80% de los ACV se pueden preveni...

Full description

Autores:
Rodríguez Rocha, Wiston Alberto
Tipo de recurso:
Fecha de publicación:
2020
Institución:
Universidad Autónoma de Bucaramanga - UNAB
Repositorio:
Repositorio UNAB
Idioma:
spa
OAI Identifier:
oai:repository.unab.edu.co:20.500.12749/7196
Acceso en línea:
http://hdl.handle.net/20.500.12749/7196
Palabra clave:
Embolia pulmonar
Cardiopatías
Geriatría
Internal medicine
Medicine
Medical sciences
Health sciences
Atrial fibrillation
Anticoagulants
Therapeutic adherence
Fragility
Pulmonary embolism
Heart diseases
Geriatrics
Medicina interna
Medicina
Ciencias médicas
Ciencias de la salud
Fibrilación auricular
Anticoagulantes
Adherencia terapéutica
Fragilidad
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UNAB2_24d3100a75bfe3329ef7bef4a7755f30
oai_identifier_str oai:repository.unab.edu.co:20.500.12749/7196
network_acronym_str UNAB2
network_name_str Repositorio UNAB
repository_id_str
dc.title.spa.fl_str_mv Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
dc.title.translated.eng.fl_str_mv Factors associated with adherence to oral anticoagulant treatment in patients with nonvalvular atrial fibrillation over 65 years of age
title Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
spellingShingle Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
Embolia pulmonar
Cardiopatías
Geriatría
Internal medicine
Medicine
Medical sciences
Health sciences
Atrial fibrillation
Anticoagulants
Therapeutic adherence
Fragility
Pulmonary embolism
Heart diseases
Geriatrics
Medicina interna
Medicina
Ciencias médicas
Ciencias de la salud
Fibrilación auricular
Anticoagulantes
Adherencia terapéutica
Fragilidad
title_short Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
title_full Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
title_fullStr Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
title_full_unstemmed Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
title_sort Factores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 años
dc.creator.fl_str_mv Rodríguez Rocha, Wiston Alberto
dc.contributor.advisor.spa.fl_str_mv Cadena Sanabria, Miguel Oswaldo
Ochoa Vera, Miguel Enrique
dc.contributor.author.spa.fl_str_mv Rodríguez Rocha, Wiston Alberto
dc.contributor.cvlac.*.fl_str_mv https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001339250
https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000898465
dc.contributor.googlescholar.*.fl_str_mv https://scholar.google.es/citations?hl=es&user=8fdkkOoAAAAJ
https://scholar.google.es/citations?hl=es&user=jQUx5WcAAAAJ
dc.contributor.orcid.*.fl_str_mv https://orcid.org/0000-0001-9807-3029
https://orcid.org/0000-0002-4552-3388
dc.contributor.scopus.*.fl_str_mv https://www.scopus.com/authid/detail.uri?authorId=56437735000
https://www.scopus.com/authid/detail.uri?authorId=36987156500
dc.contributor.researchgate.*.fl_str_mv https://www.researchgate.net/profile/Miguel_Cadena-Sanabria
https://www.researchgate.net/profile/Miguel_Ochoa7
dc.subject.mesh.spa.fl_str_mv Embolia pulmonar
Cardiopatías
Geriatría
topic Embolia pulmonar
Cardiopatías
Geriatría
Internal medicine
Medicine
Medical sciences
Health sciences
Atrial fibrillation
Anticoagulants
Therapeutic adherence
Fragility
Pulmonary embolism
Heart diseases
Geriatrics
Medicina interna
Medicina
Ciencias médicas
Ciencias de la salud
Fibrilación auricular
Anticoagulantes
Adherencia terapéutica
Fragilidad
dc.subject.keywords.eng.fl_str_mv Internal medicine
Medicine
Medical sciences
Health sciences
Atrial fibrillation
Anticoagulants
Therapeutic adherence
Fragility
Pulmonary embolism
Heart diseases
Geriatrics
dc.subject.lemb.spa.fl_str_mv Medicina interna
Medicina
Ciencias médicas
dc.subject.proposal.spa.fl_str_mv Ciencias de la salud
Fibrilación auricular
Anticoagulantes
Adherencia terapéutica
Fragilidad
description La fibrilación auricular no valvular (FANV) es la arrimia cardiaca más frecuente y su prevalencia aumenta proporcionalmente con la edad. Esta se relaciona con desenlances desfavorables como muerte, accidentes cerebrovasculares (ACV) y discapacidad. Aproximadamente el 80% de los ACV se pueden prevenir con el tratamiento anticoagulante oral (ACO), beneficio que es condicionado por una adecuada adherencia terapéutica. No existen estudios en Colombia que determinen cuales son los factores asociados con la adherencia al tratamiento anticoagulante en adultos mayores de 65 años ni la prevalencia de fragilidad en esta población, necesidad que justifica la realización del presente estudio. Objetivo: Determinar cuales factores se encuentran relacionados con la adherencia al tratamiento (ACO) de pacientes con FANV mayores de 65 años y determinar la prevalencia de fragilidad en la cohorte. Metodología: Estudio observacional analítico de corte transversal realizado en la clínica de anticoagulación de la clínica FOSCAL en pacientes con FANV mayores de 65 años. Se evaluó la adherencia terapéutica por la escala de Morisky 8 y la fragilidad por la escala FRAIL de manera telepresencial. Se realizó un análisis descriptivo de las variables sociodemográficas, clínicas y de fragilidad, luego se realizó un análisis bivariado para determinar cuáles variables independientes se relacionaron con una buena o mala adherencia. Se aceptó como significancia estadística un valor de p < 0.05. Resultados: Se recolectaron 102 pacientes (47% femenino y 53% masculino), con una promedio de edad de 76 años (mín 65 y máx 97 años). Las comorbilidades más frecuentes fueron HTA, insuficiencia cardiaca, dislipidemia, ERC y DM. Se encontró que la adherencia fue baja en el 42,1%, moderada en el 23,5% y alta en el 34,3% de los casos. La razón principal que refirieron los pacientes fue el olvido en la toma de su medicamento (50%). Las variables asociadas con una baja adherencia fueron la inconformidad con el despacho del medicamento OR 2,97 (IC 95% 1.1 – 8.2 - p 0,02) y el despacho inoportuno OR 5.85 (IC 95% 1.5 – 32.8 - p 0,005). La toma de antiagregantes plaquetarios (p 0,04) y la presencia de polifarmacia (p 0,04) se asociaron con una moderada-alta adherencia. La prevalencia de fragilidad fue del 50,9% y no tuvo impacto en la adherencia terapéutica (p 0,95). Conclusiones: La adherencia al tratamiento anticoagulante oral en pacientes con FANV mayores de 65 años fue en su mayoría moderada a baja. Las variables asociadas con menor adherencia fueron las relacionadas con el sumunistro de medicamentos. La fragilidad es una condición frecuente en adultos mayores con FANV, sin embargo esta no se asoció con mayor o menor adherencia y por tanto no debería condicionar la prescripción de la terapia anticoagulante si está clínicamente indicada. Es importante incluir la evaluación sistemática de la adherencia terapéutica en pacientes mayores para identificar factores que puedan modificar el beneficio esperado. Se sugiere establecer procesos administrativos diferenciales en pacientes que reciben ACODs con el objetivo de evitar inconvenientes administrativos con las autorizaciones y despachos del medicamento.
publishDate 2020
dc.date.accessioned.none.fl_str_mv 2020-08-22T01:41:55Z
dc.date.available.none.fl_str_mv 2020-08-22T01:41:55Z
dc.date.issued.none.fl_str_mv 2020-06-08
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.local.spa.fl_str_mv Tesis
dc.type.redcol.none.fl_str_mv http://purl.org/redcol/resource_type/TM
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.12749/7196
dc.identifier.instname.spa.fl_str_mv instname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional UNAB
dc.identifier.repourl.spa.fl_str_mv repourl:https://repository.unab.edu.co
url http://hdl.handle.net/20.500.12749/7196
identifier_str_mv instname:Universidad Autónoma de Bucaramanga - UNAB
reponame:Repositorio Institucional UNAB
repourl:https://repository.unab.edu.co
dc.language.iso.spa.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837–47.
2. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet [Internet]. 2015;386(9989):154–62. Available from: http://dx.doi.org/10.1016/S0140- 6736(14)61774-8
3. Correia M, Magalhães R, Lopes G, Araújo E. Epidemiology of atrial fibrillation. Atr Fibrillation Causes, Diagnosis Treat Options [Internet]. 2014;41–51. Available from: http://dx.doi.org/10.1038/nrcardio.2014.118
4. Petidier Torregrossa R, Abizanda Soler P, Noguerón García A, Gonzalo Lázaro M, Gutiérrez Rodríguez J, Gil Gregorio P, et al. Oral anticoagulation therapy in the elderly population with atrial fibrillation. A review article. Rev Esp Geriatr Gerontol [Internet]. 2018;53(6):344–55. Available from: https://doi.org/10.1016/j.regg.2018.04.450
5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC AF Guidelines. Eur Heart J [Internet]. 2016;(March):ehw210. Available from: http://eurheartj.oxfordjournals.org/lookup/doi/10.1093/eurheartj/ehw210
6. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT- AF). Am Heart J [Internet]. 2014;167(5):735-742.e2. Available from: http://dx.doi.org/10.1016/j.ahj.2014.02.003
7. Yamashiro K, Kurita N, Tanaka R, Ueno Y, Miyamoto N, Hira K, et al. Adequate Adherence to Direct Oral Anticoagulant is Associated with Reduced Ischemic Stroke Severity in Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis [Internet]. 2019;28(6):1773–80. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.019
8. Yao X, Abraham NS, Caleb Alexander G, Crown W, Montori VM, Sangaralingham LR, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):1–12.
9. Calkins H, Field ME, Chen LY, Furie KL, Cigarroa JE, Heidenreich PA, et al. Guideline for the Management of Patients With Atrial Fibrillation ACC/AHA. Am Hear Assoc. 2019;125–51.
10. Pava-Molano LF, Perafán-Bautista PE. Pava Molano, Luis Fernando ∗ y Pablo E. Perafán-Bautista. Rev Colomb Cardiol [Internet]. 2017; Available from: http://www.siacardio.com/wp-content/uploads/2015/01/Guias-Colombianas- FA-SCC_CCE.pdf
11. Miyazaki M, Nakashima A, Nakamura Y, Sakamoto Y, Matsuo K, Goto M, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study. PLoS One. 2018;13(9):1–13.
12. Grześk G, Janiszewska E, Malinowski B, Kubica A, Wiciński M. Adherence in patients with atrial fibrillation treated with dabigatran. Kardiol Pol. 2018;76(11):1562–3.
13. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med [Internet]. 2012;125(8):773–8. Available from: http://dx.doi.org/10.1016/j.amjmed.2012.01.033
14. Andreotti F, Rocca B, Husted S, Ajjan RA, Berg J Ten, Cattaneo M, et al. Antithrombotic therapy in the elderly: Expert position paper of the European society of cardiology working group on thrombosis. Eur Heart J. 2015;36(46):3238–49.
15. Cadena-Sanabrial MO, Pinto Saavedra OM, Contreras-Valero JF, Ortega- Ramírez GE B-MH. Oral anticlotting in the fragile elderly with atrial fibrillation. MedUNAB 2017; 19(3): 221-229.
16. Aronson JK. One hundred years of atrial fibrillation. Br J Clin Pharmacol. 2005;60(4):345–6.
17. MacKenzie J. New methods of studying affections of the heart. The inception of the rhythm of the heart by the ventricle. Br Med J 1905;1812–5.
18. Lewis T. Auricular fibrillation: a common clinical condition. Br Med J 1909;21528. :1528.
19. Diego Rosselli. Prevalencia de fibrilación auricular en un hospital universitario Colombiano. Rev Colomb Cardiol. 2013;20(6):383–5.
20. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98(10):946–52.
21. Forero-Gómez JE, Moreno JM, Agudelo CA, Rodríguez-Arias EA, Sánchez- Moscoso PA. Fibrilación auricular: Enfoque para el médico no cardiólogo. Iatreia. 2017;30(4):404–22.
22. Ramírez JD, Agudelo JF, Correa R, González E. Pathophysiology of atrial fibrillation. Rev Colomb Cardiol. 2016;23(S5):9–14.
23. Mora-Pab G. Assessment of atrial fibrillation by means of electrocardiogram and Holter. Rev Colomb Cardiol. 2016;23(S5):27–33.
24. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular , desarrollada en colaboración con la EACTS Grupo de Trabajo de la Sociedad Europea de Cardiología ( ESC ) para el diagnóstico y tratamiento Aprobada por la European Stroke Organ. Rev Esp Cardiol. 2016;70(1):1–84.
25. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke. 2013;44(11):3103–8.
26. Robert G. Hart. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
27. Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504.
28. Connolly SJ. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364(9):806–17.
29. Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493– 503.
30. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GYH, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol [Internet]. 2012;11(3):225–31. Available from: http://dx.doi.org/10.1016/S1474-4422(12)70017-0
31. Belgaid DR, Khan Z, Zaidi M, Hobbs A. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy the PREVAIL trial. Int J Cardiol [Internet]. 2016;219(1):177–9. Available from: http://dx.doi.org/10.1016/j.jacc.2014.04.029
32. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation a randomized clinical trial. JAMA - J Am Med Assoc. 2014;312(19):1988–98.
33. Melgarejo-Rojas E. Pharmacological prevention of embolism in atrial fibrillation and their risk scales for embolism and bleeding. Rev Colomb Cardiol. 2016;23(S5):65–72.
34. Zafra JT. Use of warfarin in neurology. Acta Neurol Colomb. 2010;26(2):25– 34.
35. Miranda H, Osorio S, Giraldo DP, Duque J, Cataño JU, Tobon LI, et al. Tiempo en rango terapéutico (TRT) en clínica de anticoagulación. Acta Médica Colomb [Internet]. 2016;41(1):42–8. Available from: http://www.scielo.org.co/pdf/amc/v41n1/0120-2448-amc-41-01-00042.pdf
36. Sandoval-Riveros C. Evaluación del SAMe-TTR2 score en la predicción de un mal control de la anticoagulación con warfarina en pacientes con fibrilación auricular no valvular. 2017.
37. Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Rev Española Cardiol. 2013;13(1 SUPPL.3):33–41.
38. Connolly SJ. Dabigatran versus Warfarin in Patients with Atrial Fibrillation Stuart. N Engl J Med [Internet]. 2013;368(25):2355–65. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1214609
39. Manesh R. Patel. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–91.
40. Granger CB. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–92.
41. Kim S wook, Yoon S ji, Choi J yeon, Kang M gu, Cho Y, Oh IY, et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Arch Gerontol Geriatr [Internet]. 2017;70:1–7. Available from: http://dx.doi.org/10.1016/j.archger.2016.12.001
42. Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, et al. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6(7).
43. Organización Mundial de la Salud (OMS). Adherencia a los tratamientos a largo plazo: pruebas para la acción. [Internet]. ISBN 92 75 325499. 2004. p. 3. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid =18722&Itemid=
44. Dilla T, Valladares A, Lizán L, Sacristán JA. Treatment adherence and persistence: Causes, consequences and improvement strategies. Aten Primaria. 2009;41(6):342–8.
45. Pagès-Puigdemont N. Methods to assess medication adherence. Ars Pharm [Internet]. 2018;59(3):163–72. Available from: %0Ascielo.isciii.es/pdf/ars/v59n3/2340-9894-ars-59-03-163.pdf%0A%0A
46. Morisky DE, Green LW LD. Concurrent and predictive validity of a self- reported measure of medication adherence. Med Care [Internet]. 24(1):67–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/3945130
47. Nguyen TMU, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring?: A systematic review. Br J Clin Pharmacol. 2014;77(3):427–45.
48. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.
49. Chaves Torres NM, Echeverri Sarmiento JE, Ballesteros DA, Quijano Rodriguez J, Camacho D. Validación de la escala de Morisky de 8 ítems en pacientes con enfermedad renal crónica. Rev Med. 2016;24(2):23–32.
50. Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174(1):30–42.
51. Horne R, Weinman J, Barber N, Elliott R. Concordance, adherence and compliance in medicine taking Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). Natl Co-ord Cent NHS Serv Deliv Organ R D. 2005;1–331.
52. Mantilla-Villabona LY, Ospina-Galeano DC, Gutiérrez-Ortiz AJ, Camacho PA. Patients with atrial fibrillation treated in a Primary Care clinic of a high complexity health facility. Rev Colomb Cardiol [Internet]. 2018;25(2):124–30. Available from: https://doi.org/10.1016/j.rccar.2017.09.005
53. Gumbinger C, Holstein T, Stock C, Rizos T, Horstmann S, Veltkamp R. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol. 2015;73(3–4):184–91.
54. Rosas-Carrasco O, Cruz-Arenas E, Parra-Rodríguez L, García-González AI, Contreras-González LH, Szlejf C. Cross-Cultural Adaptation and Validation of the FRAIL Scale to Assess Frailty in Mexican Adults. J Am Med Dir Assoc [Internet]. 2016;17(12):1094–8. Available from: http://dx.doi.org/10.1016/j.jamda.2016.07.008
55. Emren SV, Şenöz O, Bilgin M, Beton O, Aslan A, Taşkin U, et al. Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb. 2018;24(3):525–31.
56. Salmasi S, Loewen PS, Tandun R, Andrade JG, De Vera MA. Adherence to oral anticoagulants among patients with atrial fibrillation: A systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):1–14.
57. Solano MH, Mendieta FA. Adherence to Anticoagulant therapy. Repert Med y Cirugía [Internet]. 2014;23(3):189–98. Available from: http://repertorio.fucsalud.edu.co/images/stories/vol23/189-198.pdf
58. Odo R. Hidden Epidemic. Soc Work Ment Health. 2003;1(3):19–34.
59. Neil WP, Shiokari CE, Burchette RJ, Stapleton D, Ovbiagele B. Mail order pharmacy use and adherence to secondary prevention drugs among stroke patients. J Neurol Sci [Internet]. 2018;390:117–20. Available from: https://doi.org/10.1016/j.jns.2018.04.001
60. Perreault S, de Denus S, White-Guay B, Côté R, Schnitzer ME, Dubé MP, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Vol. 40, Pharmacotherapy. 2020. p. 40–54.
61. Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf. 2017;26(11):1367–77.
62. Ávila CW, Aliti GB, Feijó MKF, Rabelo ER. Adhesión farmacológica al anticoagulante oral y factores que influyen en la estabilidad del índice de estandarización internacional. Rev Lat Am Enfermagem. 2011;19(1):18–25.
63. Borne RT, O’Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: Findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):1–7.
64. Fernández S, Formiga F, Camafort M, Rodrigo JC, Díez-Manglano J, Reino P, et al. Antithrombotic treatment in elderly patients with atrial fibrillation: A practical approach. BMC Cardiovasc Disord [Internet]. 2015;15(1):1–10. Available from: http://dx.doi.org/10.1186/s12872-015-0137-7
65. Mostaza JM, Suárez Fernández C, Castilla Guerra L, Suriñach JM, Tamarit JJ, Diaz Diaz JL, et al. Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: The ESPARTA study. J Comp Eff Res. 2018;7(3):223–32.
66. Deshpande CG, Kogut S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. J Manag Care Spec Pharm. 2018;24(5):430–9.
67. Willey V, Franchino-Elder J, Fu AC, Wang C, Sander S, Tan H, et al. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: A retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open. 2018;8(6):1–11.
68. McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C, et al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):980–8.
69. Bakhai A, Sandberg A, Mittendorf T, Greiner W, Oberdiek AMS, Berto P, et al. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord. 2013;13.
70. Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest. 2006;129(5):1155–66.
71. Polidoro A, Stefanelli F, Ciacciarelli M, Pacelli A, Di Sanzo D, Alessandri C. Frailty in patients affected by atrial fibrillation. Arch Gerontol Geriatr [Internet]. 2013;57(3):325–7. Available from: http://dx.doi.org/10.1016/j.archger.2013.04.014
72. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7(8):1–10.
73. Bernstein MR, John L, Sciortino S, Arambages E, Auletta D, Spyropoulos AC. Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. J Thromb Thrombolysis [Internet]. 2020;49(2):316–20. Available from: https://doi.org/10.1007/s11239-019- 02031-4
74. Wu JYF, Leung WYS, Chang S, Lee B, Zee B, Tong PCY, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: Randomised controlled trial. Br Med J. 2006;333(7567):522–5.
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.local.spa.fl_str_mv Abierto (Texto Completo)
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.*.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-SinDerivadas 2.5 Colombia
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.coverage.spatial.spa.fl_str_mv Floridablanca (Santander, Colombia)
dc.publisher.grantor.spa.fl_str_mv Universidad Autónoma de Bucaramanga UNAB
dc.publisher.faculty.spa.fl_str_mv Facultad Ciencias de la Salud
dc.publisher.program.spa.fl_str_mv Especialización en Medicina Interna
institution Universidad Autónoma de Bucaramanga - UNAB
bitstream.url.fl_str_mv https://repository.unab.edu.co/bitstream/20.500.12749/7196/4/2020_Tesis_Wiston_%20Alberto_Rodriguez_Rocha.pdf.jpg
https://repository.unab.edu.co/bitstream/20.500.12749/7196/5/2020_Licencia_Wiston_%20Alberto_Rodriguez_Rocha-5.pdf.jpg
https://repository.unab.edu.co/bitstream/20.500.12749/7196/1/2020_Tesis_Wiston_%20Alberto_Rodriguez_Rocha.pdf
https://repository.unab.edu.co/bitstream/20.500.12749/7196/2/2020_Licencia_Wiston_%20Alberto_Rodriguez_Rocha-5.pdf
https://repository.unab.edu.co/bitstream/20.500.12749/7196/3/license.txt
bitstream.checksum.fl_str_mv 907b223589727bcd4393dd6469f53b26
12fc964c68914f378cf9854b76be00d0
d3d36483acde8cd179bd0678b94f11a9
8dbc1cb6d3043f0e56abdee245b46ea6
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional | Universidad Autónoma de Bucaramanga - UNAB
repository.mail.fl_str_mv repositorio@unab.edu.co
_version_ 1814278246949191680
spelling Cadena Sanabria, Miguel Oswaldo6b29f22f-ae10-4483-865e-0d3732363bcaOchoa Vera, Miguel Enriquebf83ca83-93c9-401e-91d3-b424889e868fRodríguez Rocha, Wiston Alberto83c4107b-ddc9-4a6c-9eb3-0ca6064517cehttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0001339250https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000898465https://scholar.google.es/citations?hl=es&user=8fdkkOoAAAAJhttps://scholar.google.es/citations?hl=es&user=jQUx5WcAAAAJhttps://orcid.org/0000-0001-9807-3029https://orcid.org/0000-0002-4552-3388https://www.scopus.com/authid/detail.uri?authorId=56437735000https://www.scopus.com/authid/detail.uri?authorId=36987156500https://www.researchgate.net/profile/Miguel_Cadena-Sanabriahttps://www.researchgate.net/profile/Miguel_Ochoa7Floridablanca (Santander, Colombia)2020-08-22T01:41:55Z2020-08-22T01:41:55Z2020-06-08http://hdl.handle.net/20.500.12749/7196instname:Universidad Autónoma de Bucaramanga - UNABreponame:Repositorio Institucional UNABrepourl:https://repository.unab.edu.coLa fibrilación auricular no valvular (FANV) es la arrimia cardiaca más frecuente y su prevalencia aumenta proporcionalmente con la edad. Esta se relaciona con desenlances desfavorables como muerte, accidentes cerebrovasculares (ACV) y discapacidad. Aproximadamente el 80% de los ACV se pueden prevenir con el tratamiento anticoagulante oral (ACO), beneficio que es condicionado por una adecuada adherencia terapéutica. No existen estudios en Colombia que determinen cuales son los factores asociados con la adherencia al tratamiento anticoagulante en adultos mayores de 65 años ni la prevalencia de fragilidad en esta población, necesidad que justifica la realización del presente estudio. Objetivo: Determinar cuales factores se encuentran relacionados con la adherencia al tratamiento (ACO) de pacientes con FANV mayores de 65 años y determinar la prevalencia de fragilidad en la cohorte. Metodología: Estudio observacional analítico de corte transversal realizado en la clínica de anticoagulación de la clínica FOSCAL en pacientes con FANV mayores de 65 años. Se evaluó la adherencia terapéutica por la escala de Morisky 8 y la fragilidad por la escala FRAIL de manera telepresencial. Se realizó un análisis descriptivo de las variables sociodemográficas, clínicas y de fragilidad, luego se realizó un análisis bivariado para determinar cuáles variables independientes se relacionaron con una buena o mala adherencia. Se aceptó como significancia estadística un valor de p < 0.05. Resultados: Se recolectaron 102 pacientes (47% femenino y 53% masculino), con una promedio de edad de 76 años (mín 65 y máx 97 años). Las comorbilidades más frecuentes fueron HTA, insuficiencia cardiaca, dislipidemia, ERC y DM. Se encontró que la adherencia fue baja en el 42,1%, moderada en el 23,5% y alta en el 34,3% de los casos. La razón principal que refirieron los pacientes fue el olvido en la toma de su medicamento (50%). Las variables asociadas con una baja adherencia fueron la inconformidad con el despacho del medicamento OR 2,97 (IC 95% 1.1 – 8.2 - p 0,02) y el despacho inoportuno OR 5.85 (IC 95% 1.5 – 32.8 - p 0,005). La toma de antiagregantes plaquetarios (p 0,04) y la presencia de polifarmacia (p 0,04) se asociaron con una moderada-alta adherencia. La prevalencia de fragilidad fue del 50,9% y no tuvo impacto en la adherencia terapéutica (p 0,95). Conclusiones: La adherencia al tratamiento anticoagulante oral en pacientes con FANV mayores de 65 años fue en su mayoría moderada a baja. Las variables asociadas con menor adherencia fueron las relacionadas con el sumunistro de medicamentos. La fragilidad es una condición frecuente en adultos mayores con FANV, sin embargo esta no se asoció con mayor o menor adherencia y por tanto no debería condicionar la prescripción de la terapia anticoagulante si está clínicamente indicada. Es importante incluir la evaluación sistemática de la adherencia terapéutica en pacientes mayores para identificar factores que puedan modificar el beneficio esperado. Se sugiere establecer procesos administrativos diferenciales en pacientes que reciben ACODs con el objetivo de evitar inconvenientes administrativos con las autorizaciones y despachos del medicamento.PLANTEAMIENTO DEL PROBLEMA Y JUSTIFICACIÓN 12 OBJETIVOS 14 GENERAL 14 ESPECÍFICOS 14 MARCO TEÓRICO 14 DEFINICIÓN E HISTORIA DE LA FIBRILACIÓN AURICULAR 14 EPIDEMIOLOGÍA 15 ETIOLOGÍA, PATOGENIA Y FACTORES DE RIESGO 15 DIAGNÓSTICO Y CLASIFICACIÓN 17 TRATAMIENTO ANTICOAGULANTE 19 ADHERENCIA AL TRATAMIENTO ANTICOAGULANTE 26 ESTADO DEL ARTE 31 HIPÓTESIS 33 METODOLOGÍA 33 DISEÑO DEL ESTUDIO 33 LUGARES 33 POBLACIÓN 33 CRITERIOS DE INCLUSIÓN 34 CRITERIOS DE EXCLUSIÓN 34 CÁLCULO DE TAMAÑO DE MUESTRA 34 MUESTREO 35 PLAN DE RECOLECCIÓN DE LA INFORMACIÓN 35 VARIABLES 36 CONTROL DE CALIDAD DE LOS DATOS 45 MONITOREO DE LOS DATOS 45 MANEJO DE LOS DATOS 45 PLAN DE ANÁLISIS DE DATOS 45 RESULTADOS E IMPACTOS ESPERADOS 46 DISPOSICIONES VIGENTES 48 IMPACTO AMBIENTAL DEL PROYECTO 48 CONSIDERACIONES ÉTICAS 48 CRONOGRAMA DE ACTIVIDADES 50 PRESUPUESTO 50 RESULTADOS 51 ANÁLISIS DESCRIPTIVO 52 ANÁLISIS BIVARIADO 61 DISCUSIÓN 70 CONCLUSIONES 77 REFERENCIAS BIBLIOGRÁFICAS 78 ANEXOS 87EspecializaciónNonvalvular atrial fibrillation (NVAF) is the most frequent cardiac arrhythmia and its prevalence increases proportionally with age. This is related to unfavorable outcomes such as death, strokes (strokes) and disability. Approximately 80% of strokes can be prevented with oral anticoagulant treatment (ACO), a benefit that is conditioned by adequate therapeutic adherence. There are no studies in Colombia that determine which factors are associated with adherence to anticoagulant treatment in adults over 65 years of age, nor the prevalence of frailty in this population, a need that justifies the performance of this study. Objective: To determine which factors are related to the adherence to treatment (OAC) of patients with NVAF older than 65 years and to determine the prevalence of frailty in the cohort. Methods: Observational analytical cross-sectional study carried out in the anticoagulation clinic of the FOSCAL clinic in patients with NVAF older than 65 years. Therapeutic adherence was evaluated by the Morisky 8 scale and fragility by the FRAIL scale in a telepresence way. A descriptive analysis of the sociodemographic, clinical and frailty variables was performed, then a bivariate analysis was performed to determine which independent variables were related to good or bad adherence. A value of p <0.05 was accepted as statistical significance. Results: 102 patients were collected (47% female and 53% male), with an average age of 76 years (min 65 and max 97 years). The most frequent comorbidities were hypertension, heart failure, dyslipidemia, CKD, and DM. Adherence was found to be low in 42.1%, moderate in 23.5% and high in 34.3% of cases. The main reason reported by patients was forgetfulness in taking their medication (50%). The variables associated with low adherence were nonconformity with the dispensing of the drug OR 2.97 (95% CI 1.1 - 8.2 - p 0.02) and the inappropriate timing OR 5.85 (95% CI 1.5 - 32.8 - p 0.005). Taking antiplatelet agents (p 0.04) and the presence of polypharmacy (p 0.04) were associated with moderate-high adherence. The prevalence of frailty was 50.9% and had no impact on therapeutic adherence (p 0.95). Conclusions: Adherence to oral anticoagulant treatment in patients with NVAF older than 65 years was mostly moderate to low. The variables associated with less adherence were those related to the supply of medications. Frailty is a frequent condition in older adults with NVAF, however this was not associated with more or less adherence and therefore should not condition the prescription of anticoagulant therapy if it is clinically indicated. It is important to include the systematic evaluation of therapeutic adherence in older patients to identify factors that can modify the expected benefit. It is suggested to establish differential administrative processes in patients receiving DOACs in order to avoid administrative inconveniences with the authorizations and dispatches of the medication.application/pdfspahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Abierto (Texto Completo)info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial-SinDerivadas 2.5 ColombiaEmbolia pulmonarCardiopatíasGeriatríaInternal medicineMedicineMedical sciencesHealth sciencesAtrial fibrillationAnticoagulantsTherapeutic adherenceFragilityPulmonary embolismHeart diseasesGeriatricsMedicina internaMedicinaCiencias médicasCiencias de la saludFibrilación auricularAnticoagulantesAdherencia terapéuticaFragilidadFactores asociados con la adherencia al tratamiento anticoagulante oral de pacientes con fibrilación auricular no valvular mayores de 65 añosFactors associated with adherence to oral anticoagulant treatment in patients with nonvalvular atrial fibrillation over 65 years of ageEspecialista en Medicina InternaUniversidad Autónoma de Bucaramanga UNABFacultad Ciencias de la SaludEspecialización en Medicina Internainfo:eu-repo/semantics/masterThesisTesishttp://purl.org/redcol/resource_type/TM1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129(8):837–47.2. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet [Internet]. 2015;386(9989):154–62. Available from: http://dx.doi.org/10.1016/S0140- 6736(14)61774-83. Correia M, Magalhães R, Lopes G, Araújo E. Epidemiology of atrial fibrillation. Atr Fibrillation Causes, Diagnosis Treat Options [Internet]. 2014;41–51. Available from: http://dx.doi.org/10.1038/nrcardio.2014.1184. Petidier Torregrossa R, Abizanda Soler P, Noguerón García A, Gonzalo Lázaro M, Gutiérrez Rodríguez J, Gil Gregorio P, et al. Oral anticoagulation therapy in the elderly population with atrial fibrillation. A review article. Rev Esp Geriatr Gerontol [Internet]. 2018;53(6):344–55. Available from: https://doi.org/10.1016/j.regg.2018.04.4505. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC AF Guidelines. Eur Heart J [Internet]. 2016;(March):ehw210. Available from: http://eurheartj.oxfordjournals.org/lookup/doi/10.1093/eurheartj/ehw2106. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, et al. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT- AF). Am Heart J [Internet]. 2014;167(5):735-742.e2. Available from: http://dx.doi.org/10.1016/j.ahj.2014.02.0037. Yamashiro K, Kurita N, Tanaka R, Ueno Y, Miyamoto N, Hira K, et al. Adequate Adherence to Direct Oral Anticoagulant is Associated with Reduced Ischemic Stroke Severity in Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis [Internet]. 2019;28(6):1773–80. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.0198. Yao X, Abraham NS, Caleb Alexander G, Crown W, Montori VM, Sangaralingham LR, et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016;5(2):1–12.9. Calkins H, Field ME, Chen LY, Furie KL, Cigarroa JE, Heidenreich PA, et al. Guideline for the Management of Patients With Atrial Fibrillation ACC/AHA. Am Hear Assoc. 2019;125–51.10. Pava-Molano LF, Perafán-Bautista PE. Pava Molano, Luis Fernando ∗ y Pablo E. Perafán-Bautista. Rev Colomb Cardiol [Internet]. 2017; Available from: http://www.siacardio.com/wp-content/uploads/2015/01/Guias-Colombianas- FA-SCC_CCE.pdf11. Miyazaki M, Nakashima A, Nakamura Y, Sakamoto Y, Matsuo K, Goto M, et al. Association between medication adherence and illness perceptions in atrial fibrillation patients treated with direct oral anticoagulants: An observational cross-sectional pilot study. PLoS One. 2018;13(9):1–13.12. Grześk G, Janiszewska E, Malinowski B, Kubica A, Wiciński M. Adherence in patients with atrial fibrillation treated with dabigatran. Kardiol Pol. 2018;76(11):1562–3.13. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med [Internet]. 2012;125(8):773–8. Available from: http://dx.doi.org/10.1016/j.amjmed.2012.01.03314. Andreotti F, Rocca B, Husted S, Ajjan RA, Berg J Ten, Cattaneo M, et al. Antithrombotic therapy in the elderly: Expert position paper of the European society of cardiology working group on thrombosis. Eur Heart J. 2015;36(46):3238–49.15. Cadena-Sanabrial MO, Pinto Saavedra OM, Contreras-Valero JF, Ortega- Ramírez GE B-MH. Oral anticlotting in the fragile elderly with atrial fibrillation. MedUNAB 2017; 19(3): 221-229.16. Aronson JK. One hundred years of atrial fibrillation. Br J Clin Pharmacol. 2005;60(4):345–6.17. MacKenzie J. New methods of studying affections of the heart. The inception of the rhythm of the heart by the ventricle. Br Med J 1905;1812–5.18. Lewis T. Auricular fibrillation: a common clinical condition. Br Med J 1909;21528. :1528.19. Diego Rosselli. Prevalencia de fibrilación auricular en un hospital universitario Colombiano. Rev Colomb Cardiol. 2013;20(6):383–5.20. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98(10):946–52.21. Forero-Gómez JE, Moreno JM, Agudelo CA, Rodríguez-Arias EA, Sánchez- Moscoso PA. Fibrilación auricular: Enfoque para el médico no cardiólogo. Iatreia. 2017;30(4):404–22.22. Ramírez JD, Agudelo JF, Correa R, González E. Pathophysiology of atrial fibrillation. Rev Colomb Cardiol. 2016;23(S5):9–14.23. Mora-Pab G. Assessment of atrial fibrillation by means of electrocardiogram and Holter. Rev Colomb Cardiol. 2016;23(S5):27–33.24. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular , desarrollada en colaboración con la EACTS Grupo de Trabajo de la Sociedad Europea de Cardiología ( ESC ) para el diagnóstico y tratamiento Aprobada por la European Stroke Organ. Rev Esp Cardiol. 2016;70(1):1–84.25. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke. 2013;44(11):3103–8.26. Robert G. Hart. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.27. Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study. J Thromb Haemost. 2015;13(4):495–504.28. Connolly SJ. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011;364(9):806–17.29. Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493– 503.30. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GYH, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol [Internet]. 2012;11(3):225–31. Available from: http://dx.doi.org/10.1016/S1474-4422(12)70017-031. Belgaid DR, Khan Z, Zaidi M, Hobbs A. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy the PREVAIL trial. Int J Cardiol [Internet]. 2016;219(1):177–9. Available from: http://dx.doi.org/10.1016/j.jacc.2014.04.02932. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation a randomized clinical trial. JAMA - J Am Med Assoc. 2014;312(19):1988–98.33. Melgarejo-Rojas E. Pharmacological prevention of embolism in atrial fibrillation and their risk scales for embolism and bleeding. Rev Colomb Cardiol. 2016;23(S5):65–72.34. Zafra JT. Use of warfarin in neurology. Acta Neurol Colomb. 2010;26(2):25– 34.35. Miranda H, Osorio S, Giraldo DP, Duque J, Cataño JU, Tobon LI, et al. Tiempo en rango terapéutico (TRT) en clínica de anticoagulación. Acta Médica Colomb [Internet]. 2016;41(1):42–8. Available from: http://www.scielo.org.co/pdf/amc/v41n1/0120-2448-amc-41-01-00042.pdf36. Sandoval-Riveros C. Evaluación del SAMe-TTR2 score en la predicción de un mal control de la anticoagulación con warfarina en pacientes con fibrilación auricular no valvular. 2017.37. Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Rev Española Cardiol. 2013;13(1 SUPPL.3):33–41.38. Connolly SJ. Dabigatran versus Warfarin in Patients with Atrial Fibrillation Stuart. N Engl J Med [Internet]. 2013;368(25):2355–65. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa121460939. Manesh R. Patel. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883–91.40. Granger CB. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981–92.41. Kim S wook, Yoon S ji, Choi J yeon, Kang M gu, Cho Y, Oh IY, et al. Clinical implication of frailty assessment in older patients with atrial fibrillation. Arch Gerontol Geriatr [Internet]. 2017;70:1–7. Available from: http://dx.doi.org/10.1016/j.archger.2016.12.00142. Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, et al. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6(7).43. Organización Mundial de la Salud (OMS). Adherencia a los tratamientos a largo plazo: pruebas para la acción. [Internet]. ISBN 92 75 325499. 2004. p. 3. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid =18722&Itemid=44. Dilla T, Valladares A, Lizán L, Sacristán JA. Treatment adherence and persistence: Causes, consequences and improvement strategies. Aten Primaria. 2009;41(6):342–8.45. Pagès-Puigdemont N. Methods to assess medication adherence. Ars Pharm [Internet]. 2018;59(3):163–72. Available from: %0Ascielo.isciii.es/pdf/ars/v59n3/2340-9894-ars-59-03-163.pdf%0A%0A46. Morisky DE, Green LW LD. Concurrent and predictive validity of a self- reported measure of medication adherence. Med Care [Internet]. 24(1):67–74. Available from: https://www.ncbi.nlm.nih.gov/pubmed/394513047. Nguyen TMU, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring?: A systematic review. Br J Clin Pharmacol. 2014;77(3):427–45.48. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008;10(5):348–54.49. Chaves Torres NM, Echeverri Sarmiento JE, Ballesteros DA, Quijano Rodriguez J, Camacho D. Validación de la escala de Morisky de 8 ítems en pacientes con enfermedad renal crónica. Rev Med. 2016;24(2):23–32.50. Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174(1):30–42.51. Horne R, Weinman J, Barber N, Elliott R. Concordance, adherence and compliance in medicine taking Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). Natl Co-ord Cent NHS Serv Deliv Organ R D. 2005;1–331.52. Mantilla-Villabona LY, Ospina-Galeano DC, Gutiérrez-Ortiz AJ, Camacho PA. Patients with atrial fibrillation treated in a Primary Care clinic of a high complexity health facility. Rev Colomb Cardiol [Internet]. 2018;25(2):124–30. Available from: https://doi.org/10.1016/j.rccar.2017.09.00553. Gumbinger C, Holstein T, Stock C, Rizos T, Horstmann S, Veltkamp R. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol. 2015;73(3–4):184–91.54. Rosas-Carrasco O, Cruz-Arenas E, Parra-Rodríguez L, García-González AI, Contreras-González LH, Szlejf C. Cross-Cultural Adaptation and Validation of the FRAIL Scale to Assess Frailty in Mexican Adults. J Am Med Dir Assoc [Internet]. 2016;17(12):1094–8. Available from: http://dx.doi.org/10.1016/j.jamda.2016.07.00855. Emren SV, Şenöz O, Bilgin M, Beton O, Aslan A, Taşkin U, et al. Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb. 2018;24(3):525–31.56. Salmasi S, Loewen PS, Tandun R, Andrade JG, De Vera MA. Adherence to oral anticoagulants among patients with atrial fibrillation: A systematic review and meta-analysis of observational studies. BMJ Open. 2020;10(4):1–14.57. Solano MH, Mendieta FA. Adherence to Anticoagulant therapy. Repert Med y Cirugía [Internet]. 2014;23(3):189–98. Available from: http://repertorio.fucsalud.edu.co/images/stories/vol23/189-198.pdf58. Odo R. Hidden Epidemic. Soc Work Ment Health. 2003;1(3):19–34.59. Neil WP, Shiokari CE, Burchette RJ, Stapleton D, Ovbiagele B. Mail order pharmacy use and adherence to secondary prevention drugs among stroke patients. J Neurol Sci [Internet]. 2018;390:117–20. Available from: https://doi.org/10.1016/j.jns.2018.04.00160. Perreault S, de Denus S, White-Guay B, Côté R, Schnitzer ME, Dubé MP, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Vol. 40, Pharmacotherapy. 2020. p. 40–54.61. Maura G, Pariente A, Alla F, Billionnet C. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study. Pharmacoepidemiol Drug Saf. 2017;26(11):1367–77.62. Ávila CW, Aliti GB, Feijó MKF, Rabelo ER. Adhesión farmacológica al anticoagulante oral y factores que influyen en la estabilidad del índice de estandarización internacional. Rev Lat Am Enfermagem. 2011;19(1):18–25.63. Borne RT, O’Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: Findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):1–7.64. Fernández S, Formiga F, Camafort M, Rodrigo JC, Díez-Manglano J, Reino P, et al. Antithrombotic treatment in elderly patients with atrial fibrillation: A practical approach. BMC Cardiovasc Disord [Internet]. 2015;15(1):1–10. Available from: http://dx.doi.org/10.1186/s12872-015-0137-765. Mostaza JM, Suárez Fernández C, Castilla Guerra L, Suriñach JM, Tamarit JJ, Diaz Diaz JL, et al. Type and doses of oral anticoagulants and adherence to anticoagulant treatment in elderly patients with atrial fibrillation: The ESPARTA study. J Comp Eff Res. 2018;7(3):223–32.66. Deshpande CG, Kogut S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. J Manag Care Spec Pharm. 2018;24(5):430–9.67. Willey V, Franchino-Elder J, Fu AC, Wang C, Sander S, Tan H, et al. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: A retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open. 2018;8(6):1–11.68. McHorney CA, Ashton V, Laliberté F, Germain G, Wynant W, Crivera C, et al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(9):980–8.69. Bakhai A, Sandberg A, Mittendorf T, Greiner W, Oberdiek AMS, Berto P, et al. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord. 2013;13.70. Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest. 2006;129(5):1155–66.71. Polidoro A, Stefanelli F, Ciacciarelli M, Pacelli A, Di Sanzo D, Alessandri C. Frailty in patients affected by atrial fibrillation. Arch Gerontol Geriatr [Internet]. 2013;57(3):325–7. Available from: http://dx.doi.org/10.1016/j.archger.2013.04.01472. Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018;7(8):1–10.73. Bernstein MR, John L, Sciortino S, Arambages E, Auletta D, Spyropoulos AC. Does telehealth improve anticoagulation management in patient service centers (PSC)? A pilot project. J Thromb Thrombolysis [Internet]. 2020;49(2):316–20. Available from: https://doi.org/10.1007/s11239-019- 02031-474. Wu JYF, Leung WYS, Chang S, Lee B, Zee B, Tong PCY, et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: Randomised controlled trial. Br Med J. 2006;333(7567):522–5.THUMBNAIL2020_Tesis_Wiston_ Alberto_Rodriguez_Rocha.pdf.jpg2020_Tesis_Wiston_ Alberto_Rodriguez_Rocha.pdf.jpgIM Thumbnailimage/jpeg6173https://repository.unab.edu.co/bitstream/20.500.12749/7196/4/2020_Tesis_Wiston_%20Alberto_Rodriguez_Rocha.pdf.jpg907b223589727bcd4393dd6469f53b26MD54open access2020_Licencia_Wiston_ Alberto_Rodriguez_Rocha-5.pdf.jpg2020_Licencia_Wiston_ Alberto_Rodriguez_Rocha-5.pdf.jpgIM Thumbnailimage/jpeg10447https://repository.unab.edu.co/bitstream/20.500.12749/7196/5/2020_Licencia_Wiston_%20Alberto_Rodriguez_Rocha-5.pdf.jpg12fc964c68914f378cf9854b76be00d0MD55open accessORIGINAL2020_Tesis_Wiston_ Alberto_Rodriguez_Rocha.pdf2020_Tesis_Wiston_ Alberto_Rodriguez_Rocha.pdfTesisapplication/pdf2205960https://repository.unab.edu.co/bitstream/20.500.12749/7196/1/2020_Tesis_Wiston_%20Alberto_Rodriguez_Rocha.pdfd3d36483acde8cd179bd0678b94f11a9MD51open access2020_Licencia_Wiston_ Alberto_Rodriguez_Rocha-5.pdf2020_Licencia_Wiston_ Alberto_Rodriguez_Rocha-5.pdfLicenciaapplication/pdf385347https://repository.unab.edu.co/bitstream/20.500.12749/7196/2/2020_Licencia_Wiston_%20Alberto_Rodriguez_Rocha-5.pdf8dbc1cb6d3043f0e56abdee245b46ea6MD52metadata only accessLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repository.unab.edu.co/bitstream/20.500.12749/7196/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53open access20.500.12749/7196oai:repository.unab.edu.co:20.500.12749/71962022-11-20 09:14:13.629open accessRepositorio Institucional | Universidad Autónoma de Bucaramanga - UNABrepositorio@unab.edu.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